Nanotechnology and therapeutics
Editorial Structure
Editor-In-Chief
Mansoureh Nazari Vishkaei, Ph.D.
Specialized Lecturer, School of Pharmacy, University August 17, 1945, Jakarta, Indonesia
Dr. Mansoureh Nazari Vishkaei is an accomplished pharmaceutical scientist specializing in nanoscience, nanomedicine, and advanced drug delivery systems. Her research focuses on developing nanocarrier-based formulations for targeted cancer therapy, transdermal delivery, and natural bioactive compounds. She holds a Ph.D. in Pharmacology from Universiti Sains Malaysia, where she pioneered ethosomal and nanosuspension formulations enhancing drug bioavailability and therapeutic efficacy. Dr. Mansoureh has authored numerous scientific publications and patents in nanopharmaceutical innovation. Currently serving as R&D Manager at Takhsha Darou Behan Co., she integrates nanotechnology into pharmaceutical research, bridging the gap between laboratory discovery and clinical application for improved therapeutic outcomes.
Research area: Nanotechnology, Nanomedicine, Drug Delivery Systems, Ethosomal Formulations, Nanosuspensions, Cancer Pharmacology, Targeted Therapy, Transdermal Drug Delivery, Natural Product Formulation, Pharmacokinetics, Bioavailability Enhancement, Pharmaceutical Nanocarriers, Biomedical Nanoscience, Phytopharmaceuticals, Controlled Release Systems, Lipid-Based Nanocarriers, Nanotoxicology, Pharmacological Innovation, Nanoemulsions, Therapeutic Nanoparticles.
Associate Editors
Roya Mirzaei, Ph.D.
Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Dr. Roya Mirzaei is a researcher specializing in toxicology, cancer biology, and immunotherapy. She holds a Ph.D. in Toxicology from the Islamic Azad University of Tehran Medical Sciences and has extensive research experience in mechanistic toxicology, recombinant protein design, and mitochondrial drug delivery. Dr. Mirzaei has authored numerous peer-reviewed publications in high-impact journals and actively serves as a reviewer for international pharmaceutical journals. Her current research focuses on cellular mechanisms of toxicity and the development of targeted cancer therapeutics.
Research keywords: Toxicology; Cancer Biology; Immunotherapy; Cellular Toxicity; Mitochondrial Drug Delivery; Oxidative Stress; Recombinant Protein Engineering; Mechanistic Toxicology; Molecular Pharmacology; Nanotoxicology; Anticancer Drug Development; Apoptosis Pathways; Cellular Signaling; Biomedical Sciences; Targeted Therapy; Cytotoxicity Assays; Drug Metabolism; Nanomedicine; Biomarker Discovery; Experimental Oncology.
Hossein Khani-Meinagh, Ph.D.
Product Manager, Taksha Darou-Behan Co., Iran
Product Manager, Taksha Darou-Behan Co., Iran
Dr. Hossein Khani-Meinagh earned his Ph.D. in Organic Chemistry and Biochemistry from the University of Tabriz, Iran, focusing on synthesizing pheromone derivatives and evaluating their antimicrobial and cytotoxic activities. With extensive experience in the industrial production of APIs and excipients, he has contributed to pharmaceutical R&D, scale-up processes, and enzyme inhibition studies. His academic and industrial expertise bridges natural product synthesis, biocatalysis, and nanobiomaterials. Dr. Khani-Meinagh has authored multiple peer-reviewed publications and actively contributes to developing innovative biotechnological and biochemical solutions for the pharmaceutical and food industries.
Research Keywords: Chemistry; Biochemistry; Natural Products; Biotechnology; Bioinformatics; API Synthesis; Industrial Scale-Up; Food Industry; Nanobiomaterials; Macrocyclic Compounds; Enzyme Inhibition; Nucleoprotein Complex Architecture; Enzyme Reaction Mechanisms
Muhammad Adnan Iqbal, Ph.D.
Associate Professor, Department of Chemistry, University of Agriculture, Faisalabad, Pakistan
Associate Professor, Department of Chemistry, University of Agriculture, Faisalabad, Pakistan
Dr. Muhammad Adnan Iqbal serves as an Associate Professor at the University of Agriculture, Faisalabad, Pakistan. He earned his Ph.D. and postdoctoral fellowship in Chemistry from Universiti Sains Malaysia, specializing in inorganic, organometallic, and environmental chemistry. With over 195 publications, an h-index of 33, and more than 4,300 citations, his research spans organometallic synthesis, phytomedicine, environmental toxicology, and anticancer drug development. Dr. Iqbal has supervised numerous graduate and doctoral researchers and received multiple national research grants. His work integrates fundamental and applied chemistry for sustainable biomedical and environmental innovations.
Research Keywords: Inorganic Chemistry; Organic Synthesis; Organometallic Chemistry; N-Heterocyclic Carbenes; Phytomedicine; Anticancer Agents; Analytical Chemistry; Environmental Toxicology; Green Synthesis; Metal Complexes; Bioinorganic Chemistry; Agricultural Chemistry; Sustainable Materials Chemistry; Coordination Chemistry; Drug Design.
Mohammadreza Gholibeikian, Ph.D.
Kashan University, Iran
Dr. Mohammadreza Gholibeikian is an Associate Editor in Organic Chemistry, currently affiliated with Homapharmed Company in Tehran. He holds a PhD in Organic Chemistry from Kashan University, as well as an MSc in Organic Chemistry from the University of Semnan and a BSc in Applied Chemistry from North Tehran University. His research spans peptide and nanomedicine synthesis, bioactive natural products, and anticancer peptide design, including cyclic and linear analogues of carnosine and Longicalycinin A. Dr. Gholibeikian supervises clinical trials of herbal formulations and holds several patents in herbal therapeutics.
Research Keywords: Peptide Synthesis; Nanomedicine; Carnosine Analogues; Longicalycinin A; Anticancer Activity; Natural Products; Macrocyclization; Herbal Therapeutics; Cytotoxicity; Organic Chemistry
Pegah Zanjanchi, Ph.D.
University of Guilan, Rasht, Iran
University of Guilan, Rasht, Iran
Dr. Pegah Zanjanchi is a nanobiotechnologist specializing in the design and development of gold nanoparticle–peptide conjugates for cancer therapy and antiangiogenic applications. She earned her Ph.D. in Nanobiotechnology from the University of Isfahan with distinction, focusing on the synthesis of VEGF-antagonistic peptide–functionalized gold nanoparticles for inhibition of angiogenesis and tumor progression. Dr. Zanjanchi has published widely in high-impact journals, including Journal of Nanobiotechnology and Journal of the Iranian Chemical Society. Her multidisciplinary expertise spans nanomedicine, molecular biology, and phylogenetic systematics, with active involvement in cancer research and pharmacological innovation.
Research Keywords: Nanobiotechnology; Gold Nanoparticles; Peptide Conjugation; VEGF Inhibition; Antiangiogenesis; Cancer Therapy; Molecular Biology; Phylogenetics; Drug Delivery; Biochemistry.
Elham Davoudi, Ph.D.
Department of Biomedical and Nutritional Sciences, University of Massachusetts Lowell, USA
Department of Biomedical and Nutritional Sciences, University of Massachusetts Lowell, USA
Dr. Elham Davoudi, Pharm.D., is a Ph.D. Candidate in Pharmaceutical Sciences at the University of Massachusetts Lowell. Her research integrates computational pharmacology and experimental therapeutics, focusing on physiologically based pharmacokinetic (PBPK) modeling, ADME prediction, and dose optimization for novel drug formulations. She has extensive expertise in PK-Sim, MoBi, Simcyp, MATLAB, and SimBiology for translational modeling, as well as hands-on experience in histology, cytotoxicity, and nanoparticle formulation. Dr. Davoudi’s current projects include PBPK modeling of copper and Hinokitiol for neuro- and metabolic applications, along with translational pharmacology studies at AstraZeneca and Harvard-affiliated research collaborations.
Research Keywords: Pharmaceutical Sciences; Pharmacokinetics; PBPK Modeling; Drug–Drug Interactions; Computational Pharmacology; Nanomedicine; Translational Research; Drug Delivery; Toxicology; Systems Pharmacology.
Bushra Akhtar, Ph.D.
Department of Pharmacy, University of Agriculture Faisalabad, Pakistan
Department of Pharmacy, University of Agriculture Faisalabad, Pakistan
Dr. Bushra Akhtar, Pharm.D., M.Phil., Ph.D. (Pharmacology), is a Lecturer (BPS-18) at the Department of Pharmacy, University of Agriculture Faisalabad, Pakistan. Her research focuses on nanomedicine development, toxicity assessment, pharmacokinetics, and the therapeutic exploration of indigenous medicinal plants. With over 160 cumulative impact factor points, 64 research papers, six book chapters, and a national patent, Dr. Akhtar has made notable contributions to pharmacology and toxicology. She is also an academic editor for PLOS ONE, Evidence-Based Complementary and Alternative Medicine, and Canadian Respiratory Journal.
Research Keywords: Nanomedicine; Pharmacology; Toxicology; Pharmacokinetics; Drug Delivery; Medicinal Plants; Biomedical Research; Therapeutic Nanoparticles; Genotoxicity; Cytotoxicity.
Publication & Editorial Staff Contacts
Journal Editorial staff contact
- office@emanresearch.org
Publisher
- office@emanresearch.org
For Advertising, Commercial Reprint, and/or Recruitment Information
- Visit ER's Advertising Center
Marketing Manager
Translation, Rights & Licensing
Eman Research Business Offices
Eman Research Publishing LLC, 30 N Gould St Ste R Sheridan, WY 82801 USA
Website https://www.emanresearch.org
Submit Article
Use the online submission system to send us your manuscript.
Call for Papers
We are seeking Contributions for a special issue. More.
Best Paper Award
Authors are awarded for Best Paper for this Journal Annually
Advertisement